Abstract. We recently have demonstrated that EGF receptor (EGFR)-induced cell motility requires receptor kinase activity and autophosphorylation (P. Chen, K. Gupta, and A. Wells. 1994. J. Cell Biol. 124:547-555). This suggests that the immediate downstream effector molecule contains a src homology-2 domain. Phospholipase C3, (PLC3,) is among the candidate transducers of this signal because of its potential roles in modulating cytoskeletal dynamics. We utilized signaling-restricted EGFR mutants expressed in receptor devoid NR6 cells to determine if PLC activation is necessary for EGFR-mediated cell movement.
responsive infectant lines. Lastly, anti-sense oligonucleotides (20 #M) to PLC3,-1 reduced both responses in NR6 cells expressing wild-type EGFR. These findings strongly support PLC~/as the immediate post receptor effector in this motogenic pathway.
We have demonstrated previously that EGFRmediated cell motility and mitogenic signaling pathways are separable. The point of divergence is undefined. All kinase-active EGFR mutants induced the mitogenic response while only those which are autophosphorylated induced PLC activity. U73122 did not affect EGF-induced thymidine incorporation in these motility-responsive infectant cell lines. In addition, the dominant-negative PLC3,-1 fragment did not diminish EGF-induced thymidine incorporation. All kinase active EGFR stimulated mitogen-activated protein (MAP) kinase activity, regardless of whether the receptors induced cell movement; this EGF-induced MAP kinase activity was not affected by U73122 at concentrations that depressed the motility response. Thus, the signaling pathways which lead to motility and cell proliferation diverge at the immediate postreceptor stage, and we suggest that this is accomplished by differential activation of effector molecules.
C
ELL movement is essential for numerous normal biological and physiological events such as wound healing, fetal development, bone remodeling, angiogenesis, and the inflammatory response. Aberrant cell movement, on the other hand, contributes to the pathogenesis of many diseases, such as atherosclerosis and tumor invasion and metastasis. Cell movement is modulated by signals from extracellular environment. However, the intracellular signal phorylatable tyrosine within the carboxy-terminal regulatory region of the EGFR. Phospho-tyrosine motifs interact with src homology 2 (SH2) domains in effector molecules activating these second messengers (9, 30) ; these SH2 domain interactions with phosphotyrosines display varying degrees of specificity according to the amino acids surrounding the tyrosine (18, 26, 29, 36, 42, 43, 55) . Multiple EGFR phospho-tyrosine motifs are capable of signaling cell movement, suggesting either a promiscuity in the interactions with SH2 domains or parallel intracellular pathways leading to cell movement (11) . Thus, the search for the immediate downstream molecules that mediates the motility response has been pointed toward SH2 domain containing signal transducers.
Pbospholipase C ~, (PLCT) is activated by the EGFR tyrosine kinase after physical associating with the receptor via its SI-I2 domains (27) . PLC,y activity and subsequent effector molecules can be linked to the motogenic machinery. PLC~, is capable of associating via its SH3 domain with actin filaments (3) . PLC-y hydrolyzes PIP2 to produce IP3 and DAG. This hydrolysis releases profilin and gelsotin) actin-sequestering and -severing proteins (2, 19) . IP3 mobilizes intracellular calcium which also has been shown to modulate actin assembly (44) . These findings provide a theoretic framework for the participation of PLC~, in the pathway leading to cell motility. Recent studies have demonstrated that PLC'y activity is required for chemotactic transmigration of cells through a collagen gel in response to PDGF-BB (8, 25) . However, the cell property elicited by PLC-y activation (i.e., cell movement, enhanced gel proteolysis, etc.) is undefined.
In this study, we utilize the EGFR-devoid NR6 fibroblast cell line (33) to investigate the link between EGF-induced cell movement and PLC~/activity. Various EGFR mutants were expressed in this cell background to avoid signaling from native EGFR (20, 52) . The EGFR constructs varied in their ability to elicit a motogenic response upon activation (11) . EGF-induction of PLC3, activity and cell movement correlated closely. A pharmacological agent which specifically inhibits PLC activity abrogated induced cell movement, but had no effect on EGFR-mediated mitogenesis. Molecular inhibition of PLC,y activity by antisense oligonucleotides or a dominant-negative fragment (23) also diminished the motility response. Lastly, in an attempt to map further downstream intermediaries, activation of mitogenactivated protein (MAP) kinase was found not to be sufficient to induce cell movement.
Materials and Methods

Generation of NR6 Cells Expressing EGFR Constructs
The construction of the EGFR and stable expression in NR6 cells were by standard methods, and have been described previously (11, 52) . Briefly, wild-type (WT) EGFR is a full-length cDNA (46) derived from a placental cDNA library (53) . M TM is the kinase-inactive counterpart in which methionine replaces lysine in the ATP-binding pocket (13) . d973, c'991, and c'1000 represent EGFR in which stop codons are introduced just distal to the amino acid number indicated. CI000F 992 was created from all000 by replacing the sole remaining autophosphorylation site at y~2 with a phenylalanine (F 992) (10) . The fusion mutants c'958f 9s8-996 and c958f II'~'-"~ link a minimal kinase-active EGFR (50) to the phosphotyrosine motifs around yg~ and ytt4s, respectively, c'1186F3 represents a full-length EGFR in which the three major autophosphorylation sites (yt173, yii4s, and yi0¢,8) (17) have been negated by phenylalanine replacement. The EGFR are shown schematically in Table I. The constructs were expressed on NR6 cells, 3T3-derivatives which lack endogenous receptors (33) . This was accomplished by retroviral-mediated transduction as previously described (51) . Polyclonal lines were established by selection in G418 (GIBCO BRL, Gaithersburg, MD). The infectant cell lines presented high, but physiologic levels of receptors (50,000-250,000 EGF-binding sites per cell) with similar dissociation constants (gd were 0.2-0.7 nM); different EGFR levels within this range do not affect ligandinduced cell motility (11) . All of the EGFR possessed kinase activity, except for M72t; the cells which presented the kinase-active EGFR all demonstrated a mitogenic response to EGE
Cell Motility Assay
EGF-induced migration was assessed by the ability of the cells to move into an acellular area as previously described (11, 14) . Briefly, NR6 cells were plated on plastic and grown to confluence in MEMc~ with 7.5% FBS. After 24 h of incubation in media with 1% dialyzed FBS, an area was denuded by a rubber policeman at the center of the plate. The cells were then treated with or without 25 nM EGF and incubated at 37°C. Photographs were taken at 0 and 24 h and the relative distance traveled by the cells at the acellular front was determined. The EGF-induced migration was calculated as a percent of basal motility observed in the non-EGF-treated cells tested in parallel at each time point. Mitomycin-C (0.5 #g/ml) was present throughout the motility assays to avoid interference from the mitogenic response.
PLC Activity Assays
PLC activity was monitored by a functional assay in which the production of inositol phosphate species (IP) was measured (38, 39) . NR6 cells expressing mutant EGF receptors were grown to 'x,90% confluency, under the same conditions used in motility assays. Cells were labeled in serum free media containing 5 #Ci/ml [3H]myo-inositol for 12-14 h, after which the cells were washed twice with PBS to remove unincorporated label. LiCI (10 mM) was introduced to inhibit IP hydrolysis by inositol phosphatases. After 15 rain of LiCl incubation, saturation level of EGF (25 nM) was added and the incubation continued for another 30 rain. The reaction was terminated by removing the media and adding boiling water to the cells. Cell lysates were collected and boiled for 5 rain. The lysates were briefly centrifuged 1o remove particulate material, and the soluble cytosolic fraction retained for analysis.
Inositols and inositoi phosphates were separated on Dowex (AGI-X8 100-200 mesh) anion-exchange mini column. Inositol was eluted with water and IP with 100 mM ammonium formate and 100 mM formic acid. The IP content was quantitated by scintillation counting and normalized against the protein content in the lysate determined by Bradford Protein Assay (Bio Rad Labs., Hercules, CA). The EGF-elicited PLC activity was expressed as percent of non-EGF-treated basal IP production to account for variations in labeling.
A complete profile of the individual inositol phosphate species was generated by HPLC separation to confirm the anion-exchange chromatography (38) . Split samples from the cell lysate were injected into a Partisil 10 SAX anion-exchaoge analytical column (0.45 x 25 cm). Inositol was eluted with water for 10 min. Inositol phosphate species were eluted in the order of IP, IP2, and IP3 by a 5-min linear gradient of 0-10% 1 M ammonium formate, pH 3.8, followed by 20-rain of isocratic elution with 10% 1 M ammonium formate. Elution then continued with 25-min linear gradient of 10-100% of 1 M ammonium formate followed by a 15-min isocratic 100% 1 M ammonium formate. The flow rate was set at 1.2 ml/min and l-rain fractions were collected.
PLC activity responsiveness after prolonged EGF treatment was determined after 12 h of continuous exposure of cells to EGE After 12 h of incubation, 10 mM LiCI was added. After an additional 30-min incubation, cells were lysed and lysates were analyzed as described above.
Thymidine Incorporation Assay
EGF-induced mitogenesis was assessed by the incorporation of [3H]thymidine in the target cells. Cells were plated on plastic and grown to confluence in MEMc~ with 7.5% FBS. The ceils were then switched to media containing 1% dialyzed FBS for 24 h. The ceils were subsequently treated with or without EGF (25 nM) and incubated at 37°C for 16 h. [3H]thymidine (5 #Ci/ml) was added and incubation continued for another 10 h. The cells were then washed with ice-cold PBS twice and incubated in 5 % trichloroacetic acid at 4°C for 30 min. After two washes with PBS the cells were lysed in 0.2 N NaOH and the incorporated [3H]thymidine counted by scintillation counter.
Pharmacological PLC Inhibitors
The pharmacological agents, U73122 (l~(6-((17b-3-methoxyestra-l,3,5(10)-trien-17-yl)amino)hexyt)-lH-pyrrole-2,5-dione) and its inactive congener, U73343 (1-(6-((17b-3-methoxyestra-1,3,500)-trien-17-yl)amino)hexyl)-2,5-pyrrolidine-dione), were added to the cells to inhibit PLC activity (7, 41) . Both U73122 and U73343 (BIOMOL Res. Labs., Inc., Plymouth Meeting, PA) were dissolved in chloroform and dried under a nitrogen stream. The dried film was then dissolved in medium containing serum proteins to complex the drugs for intracellular delivery.
These compounds were introduced at 1 #M into the media in the PLC activity assays at the same time LiCI was added. In the cell migration and [3H]thymidine incorporation assays, these compounds (1 #M) were introduced 15 rain before the addition of EGE EGF-induced PLC activity and cell migration responses were measured in parallel with the control non-EGF-treated cells.
Cloning and Expression of Dominant-negative PLC'y4 in NR6 Cells
A dominant-negative PLC,y-1 gene fragment (designated as PLCz) which encodes the Z region SH2 and SH3 domains (amino acids 517-901) of this enzyme (23) was cloned from a human placenta eDNA library by standard PCR techniques. The oligonucleotide primers used were: 5' sense I517: CCTCTAGAATGATCTACTACTC'IVJAGGAGACC and 3' anti-sense stopgm: GC~AAGCTTCTACATGCTGATGGAGAAGACGAAG.
These primers have XbaI and HindIII sites to allow subsequent cloning into the pXf vector for expression. Subcloning placed the PLCz fragment under the control of a SV40 early promoter present in the pXf vector (12) . The pXf vector contains a DHFR gene transcribed from a second SV40 early promoter.
The pXf/PLCz expression vector was transfected into selected NR6 infectant cell lines (c'1000, c'1086F3, and c'991) using the lipofectin reagent (GIBCO BRL). Ceils were selected in 400 mM methotrexate. Stable expression of PLCz in these cell lines was demonstrated by western blotting with mixed monoclonal anti-PLC'y-1 antibodies (UBI; 05-163). The PLCz expressing cell lines were tested for PLC activity, cell movement, and thymidine incorporation as described above.
Anti-sense PLC-t-10tigonucleotides
Anti-sense PLC3, oligonucleotides were employed to down-regulate PLC3, expression. Oligonucleotide A1 (GGGGGTCCCGACGCCCGCCAT) was a 21-mer anti-sense to the sequence encoding the first seven amino acids in the rat PLC~ sequence. Al-thio was the same sequence with the first and the last base containing a thio-linkage to prevent degradation. A2 (GCTGTACATGAGGCTGCGGTA) was a 21-mer anti-sense to the sequence encoding the amino acids 217-223 which was absolutely conserved across murine, rat and human species. S1 (CGGAGGAAGAAGAT-TGCCCTG), a 21-mer sense oligonucleotide, encoding amino acids 945-951 in the human PLC% was used as a control to demonstrate sequence specificity of any effects. The oligonucleotides were dissolved in medium and introduced at 20 #M during the final 8 h of the metabolic labeling in the PLC activity assays. In the cell migration assays, oligonucleotides (20 #M) were introduced 8 h before the addition of EGF and remained present throughout the entire assay period. The effects of these oligonucleotides on EGF-induced PLC activity and cell migration responses were assessed in parallel with the control oligonuclcotides and nontreated ceils.
Phospholipid extraction was used to determine the basal incorporation of [3H]myo-inositol in the presence of antisense oligonucleotides. After metabolic labeling with or without oligonucleotides as described above, cells were lysed in 1 mi of cold methanol. Chloroform (0.5 ml) containing 0.63 mg/ml of butylated hydroxytoluene was added to the lysate. 188 #1 of 1:2 chloroform/methanol were added, followed by 563 /zl of water. The lower chloroform layer containing phospholipids was collected. A 200-#1 aliquot was air-dried and incorporated label measured by scintillation counting. The effects of antisense oligonucleotides were assessed in parallel with the nontreated control cells.
MAP Kinase Assay
MAP kinase activity was measured as the rate of phosphorylation of the MAP kinase-specific substrate myelin basic protein (MBP) by cell extract as previously described (1) . Briefly, cells were plated on plastic and grown to confluence. After 5 rain of treatment with EGF (25 nM), cells were rinsed twice with ice-cold PBS and once with cold extraction buffer (50 mM /~-glycerophosphate, pH 7.3, L5 mM EGTA, 0.1 mM Na3VO4, I mM dithiothreitol, 10 t~g/ml leupeptin, 10 #g/ml aprotinin, 2 #g/ml pepstatin A, and 1 mM benzamidine). Ceils were scraped into extraction buffer, homogenized for 20 s and centrifuged at 14,000 g for 5 min at 4°C. Supernatants were collected as the cytosolic extracts. The cytosolic extracts were then mixed at room temperature with the assay buffer so the final concentrations of assay components were 50 mM/3-glycemphosphate, pH 7.3, 1.5 mM EGTA, 0.1 mM Na3VO4, 1 mM dithiothreitol, 10 #M calmidazolium, 2 #M PKI peptide, 10 mM MgCIz, 0.33 mg/ml MBP, 330 nM ATE and 15 nM [32P]3,ATP. Reactions were terminated after 0, 2, 4, 6, and 10 min by spotting aliquots of the assay mixture onto PE81 phosphocellulose filter paper squares which were washed three times with 175 mM phosphoric acid, once with ethanol, once with ether, air dried, and counted. Initial studies revealed that the 10-min time period was in the linear range; MAP kinase activity was determined as the increase of MBP phosphorylation over time. The EGF-induced MAP kinase activity was determined by comparing the MAP kinase activity of EGF-treated cells to non-EGF-treated cells; the EGF-induced MAP kinase activity was calculated and expressed as the percent of activity seen in non-EGF-treated cells.
The effects of U73122 on EGF-induced MAP kinase activity was assessed. 1/zM of U73122 was introduced to the cells 15 rain before the addition of EGF and the EGF-induced MAP kinase activity was evaluated as above.
Results
EGF Induces PLC Activity Only in Cell Lines which Demonstrate EGF-enhanced Movement
Previously, we demonstrated that EGF augments cell movement only in NR6 cells that express EGFR constructs which contain at least one autophosphorylatable tyrosine (11). Cell movement was determined by the ability of cells to move into a denuded area on a culture dish. To standardize the assays, the EGF-induced movement after 24 h of EGF exposure was calculated as a percent of basal motility observed in non-EGF-treated cells tested in parallel. NR6 cells expressing EGFR constructs which undergo autophosphorylation (WT, c'1000, c958ff 8s-996, c958f a1~"54) demonstrated enhanced movement in the presence of saturating concentrations of EGF (25 nM) (Table I) ; this is in agreement with our earlier report (11) . An additional mutant dl186F3, a fulllength receptor with the three major autophosphorylatable tyrosines (yl173, yH48 and y1068 [17] ) replaced by phenylalanines, was tested for EGF-induced motility. As would be predicted (11, 43) , this construct underwent autophosphorylation upon EGF stimulation, presumably at the remaining two minor pbospho-tyrosine motifs (centered on y992 and yt086 [43, 50] 
EGF-induced PLC7 Activity and Cell Migration in NR6 Cells Expressing EGFR Constructs
conversion to IP4 and subsequent dephosphorylation. Accumulation of IP in the presence of lithium, an inhibitor of inositol monophosphatase, is a good measure of phosphoinositide signaling (5, 39) . Production of IPs was determined and quantified by anion exchange chromatography followed by scintillation counting. To account for experimental variations in metabolic labeling and extractions, IPs production was calculated as cpm per 100 #g protein; the production induced by EGF was expressed as percent of IPs produced by non-EGF-treated cells tested in parallel. We observed a concordance between EGF induced cell movement and augmerited PLC activity (Table I) . The NR6 cells expressing autophosphorylatable EGFR all demonstrated ligand stimulation of PLC activity while the cell lines presenting nonautophosphorylated EGFR did not.
HPLC separation of the inositol species confirmed that IP3 was generated from the labeled inositol pool (Fig. 1) . As lithium exerts its most potent inhibition towards inositol monophosphatase, inositol monophosphate was the major species which accumulated after EGF treatment of responsive cell lines. The low level of IP3 observed is consistent with a brief <2-5 rain burst of IP3 formation (I(1, 4, 5)P3 for the initial minute converting to I(1, 3, 4)P3 as the major species after that), followed by a prolonged lower level of IP3 generation (data not shown and reference 21).
PLC Activation by EGF Is Demonstrable Even After 12
Hours of Exposure NR6 cell movement in response to EGF is observed only after 6-12 h of exposure (11) . However, PLC activity was monitored during the initial 30 min of EGF stimulation to avoid interference from inositol turnover and recycling and depletion of [3H]-labeled inositol. Furthermore, as EGF exposure stimulates phospho-inositide metabolism (Table I , Fig. 1 ), EGF treatment may be expected to exacerbate the depletion of labeled inositol. However, it was critical to determine if IP3 production was increased throughout the migration assays.
EGF-augmented PLC activity was measured after 12 h of EGF stimulation (Fig. 2) . After metabolic labeling of NR6 cells expressing WT EGFR, the cells were washed, incubated in media without [3H]myoinositol, and either treated or not with saturation concentrations of EGF (25 nM). After a further 12-h incubation, LiC1 (10 raM) was added to prevent IP hydrolysis, and production of IP determined. Cells which were not exposed to EGF during the 12 h after labeling incubation, demonstrated significant induction of PLC activity in response to addition of EGF; the absolute amount of label recovered in the IP fraction was reduced 15-20% in cells stimulated 12 h after labeling com- IP at nearly twice the rate of unstimulated ceils. HPLC analyses revealed that IP3 was being generated at a higher rate in the EGF-exposed cells than in the non-treated cells ( Fig. 2 b) ;
Pharmacologic Agents Which Inhibit PLC Activity Also Decrease EGF-induced Cell Motility
The correlation between EGF-induced PLC activity and cell motility suggested that PLC'y is the immediate downstream effector in the EGFR-mediated motogenic pathway. However, this correlation may represent an epipbenomenon due to promiscuity of phospho-tyrosine/SH2 domain interactions (11, 35, 42) . A causal relationship between PLC3, and cell motility would be demonstrated if inhibition of PLC reduced cell movement. Pharmacological agents can inhibit specific enzymes in complex biochemical pathways. U73122 has been shown to inhibit specifically PLC while its inactive analogue U73343 does not affect this enzymatic activity (7, 41) . EGF-induced PLC activity and cell motility were determined in the presence of these agents (Fig. 3) . In three cell lines expressing responsive EGFR constructs 0NT, c'1186F3, and c'1000), U73122 inhibited EGF-induction of both PLC activity and cell movement; the inactive analogue, U73343, had little affect on these responses. We noted only partial inhibition of both PLC and cell motility at the doses used (1 and 2 ~M); higher concentrations which fully blocked EGF-induction of PLC activity (>5 pM) resulted in cell toxicity over the 12-24 h required for the motility assays (data not shown). The effect of U73122 on basal cell movement and IP production was negligible (<15% decrease) in these cell lines. 
A Dominant-negative PLC3,4 Fragment or Antisense Oligonucleotides Diminish EGF-induction of Both PLC Activity and Cell Motility
Specific interruption of EGFR activation of PLC'y is required to demonstrate a causal relation between induced PLC activity and cell motility. U73122 is not specific for the tyrosine kinase activated isoform of PLC, PLC3', and may also inhibit other phospholipases which are triggered by the EGFR (32) . Therefore, we attempted to either block the activation of PLC3, by interfering with its binding to EGFR or to down-regulate the level of PLC3, in the cell. The Z region of human PLC3,-1, covering the SH2-SH2-SH3 domains, was isolated by reverse transcriptase/PCR and cloned into a eukaryotic expression vector. PLCz was expressed in three selected infectant NR6 lines (c'1000, c'1186F3, and c'991), as determined by immunoblotting with a mixture of monoclonal antibodies (data not shown). PLC activity and cell movement were tested in these infectant sublines (Fig. 4) . The presence of PLCz disrupted both EGFinduced responses in parallel. The infectant PLCz sublines demonstrated lower basal PLC activity than their respective infectant lines, but basal cell movement was unchanged. EGF-induction of these responses was blocked or severely diminished in the PLCz sublines.
Anti-sense oligonucleotides down-regulated PLC'y activity in the WT EGFR infectant cells (Fig. 5) . The sense oligonucleotide control had no affect on EGF-induced cell responses. Two distinct anti-sense oligonucleotides were tested for the ability to decrease the EGF-induced PLC and motility responses. Accumulations of IPs were decreased by 35-60% in these cells, and augmented cell movement by 56-82 %; basal activities were relatively unaffected by these treatments. The slightly greater inhibition of cell movement compared to IP generation may be due to extended exposure to anti-sense down-regulation in the cell migration assay; the oligonucleotides were present for 8 h before addition of EGF and remained in the media throughout the 24-h motility assay. As anti-sense down-regulation does not affect previously synthesized proteins, the extended exposure in the migration assay may result in a greater decrease in PLC activity during the measurement of this response.
Induced Cell Motility Correlates with PLC Activity
EGF-induction of PLC activity was compared to induction of cell movement (Fig. 6) . NR6 cell lines which expressed . Oligonucleotide A1 was a 21-mer anti-sense to the sequence encoding the first seven amino acids in the rat PLC3, sequence. Al-thio was the same sequence with the first and the last base containing sulfur groups to prevent degradation. A2 was a 21-mer anti-sense to the sequence encoding the amino acids 217-223. A sense sequence S1, a 21-mer encoding amino acids 945-951, that was used as a control to demonstrate the inhibitory effects on PLC activity was sequence specific. The effects of these oligonucleotides on the EGF-induced responses were expressed as percent of the EGF-induced responses observed in the absence of EGF and oligonucleotide treatment. Solid bars depict PLC activity or cell migration in the absence of EGF treatment; hatched bars are EGFinduced responses. Values are mean + SD; n > 3. 
EGF-induced Mitogenesis Is Independent of the Inhibition of EGF-induced PLC Activity
We have shown previously that EGF-induced motogenesis is separate from the mitogenic response (11)" all EGFR conautophosphorylatable (Fig. 6, Y ) and non-autophosphorylatable (Fig. 6, O) EGFR represented the doubly responsive and doubly nonresponsive lines, respectively. U73122 treatment (Fig. 6, U) partially inhibited both parameters in the three responsive cell lines tested (Fig. 3) . Diminution of PLC activity correlated with reduced cell motility in the infectant sublines expressing PLCz (Fig. 6, Z) and the WT EGFR line treated with the oligonucleotides (Fig. 6, A) . EGF-induced PLC activity and cell motility was expressed as percent of basal (non-EGF-treated). The two responses structs which exhibited exo-kinase activity elicited mitogenesis, low dose D-actinomycin blocked motility but did not affect EGF-induced mitogenesis, and mitomycin-C treatment abrogated proliferation but spared the ligand-induced motility. The point of divergence of these two EGFRmediated signaling pathways is unknown. That augmented PLC activity was observed only in the cells expressing autophosphorylatable EGFR (Table I) suggested that the separation of the pathways may occur at the immediate postreceptor level. To further establish the divergence of signals, we assessed EGF-induced mitogenesis in the presence of U73122 (Fig. 7) and in infectant sublines expressing PLCz (Fig. 8) . EGF-induced mitogenesis was determined by incorporation of [3H]thymidine. At concentrations of U73122 (1 #M) that inhibit EGF-induced PLC activity and cell motility, thymidine incorporation was not diminished regardless of the aUtophosphorylation status of the expressed EGFR. In the c'1000PLCz and c'l186F3PLCz sublines, pH]thymidine incorporation, if anything, was increased, not decreased. Thus, disruption of EGFR-mediated PLC~, activity and blockage of induced cell movement does not negatively affect the mitogenic response.
Activation of M A P Kinase Is Not Sufficient to Elicit EGF-induced Cell Motility
Activation of the MAP kinase cascade has been implicated in linking receptor tyrosine kinases to numerous biological responses including mitogenesis and differentiation (15, 28) . EGFR-mediated signals activate MAP kinase; this activation, however, can be accomplished by EGFR in which the five mapped autophosphorylation sites have been replaced by phenylalanines (16) . We have shown that EGF-induced motility response requires phospho-tyrosine motifs in the receptor (11) . These findings suggested that activation of MAP kinase pathway is not sufficient to elicit cell motility.
To demonstrate that the MAP kinase activation is not sufficient for signaling cell movement, we determined the EGF-induced MAP kinase activity in NR6 cells expressing both motogenic (WT and c'1000) and nonmotogenic (c'1000b "w2 and c'973) EGFR constructs. EGF-stimulated phosphorylation of MBP was similar in cells expressing WT and c973 EGFR constructs (Figs. 9 and 10 ). Augmented MAP kinase activity was mirrored by EGF-induced tyrosyl phosphorylation of p42 MAP kinase. These findings confirm that the ability to trigger MAP kinase by an EGFR lacking the carboxy-terminal region is intrinsic to the receptor. Thus, activation of MAP kinase pathway correlates with EGF-induced mitogenesis, but this activation is not sufficient to elicit enhanced motogenesis.
Discussion
We demonstrated previously that EGF-induced cell motility requires the presence of a phospho-tyrosine motif in the intracellular regulatory region of the EGFR (11) . This suggests that the immediate downstream effector molecule in the motogenic pathway was activated by SH2 domain interactions. Numerous SH2-containing effector molecules interact with, and are activated by EGFR (9, 37, 40, 45, 49, 55) . At least three of these pathways can be linked to cell motility. Activation of small GTP-binding proteins of the rho subfamily leads to formation of focal adhesions (34) , which is con- sistent with the conclusion that activation of GAP by the PDGF/3 receptor inhibits cell movement (25) . Recent studies have demonstrated that phosphatidylinositol 3' kinase activation is required for chemotaxis signaled via the PDGF/~ receptor (25, 54) . A third signaling pathway which involves PLC3, may promote cell motility. PLC hydrolysis of PIP2 releases actin-severing and -sequestering proteins which lead to the dissolution of stress fibers and focal adhesions, enabling a cell to move (2, 19, 44) . In addition, activation of PLC-y has been shown to be required for (25, 54) or associated with (8) PDGF/3 receptor-mediated chemotaxis. The specific intermediary effector molecules in the motogenic pathway have not been investigated in other receptors with intrinsic tyrosine kinase activity. We investigated the necessity of PLC'y activation in EGFR-mediated motogenesis. We examined a series of cell lines expressing genetically engineered EGFR for EGFinduced PLC activity. Activation of PLC~ by EGFR was determined by a functional assay because EGFR may phosphorylate PLC3, without activating it (unpublished observations), presumably by phosphorylation of non-activating tyrosines (24) , and PLCq¢ may be activated non-enzymatically by EGFR (22) . Enhanced inositol phosphate production was observed only in the cell lines which demonstrate EGFR-mediated cell movement (Table I) . EGF enhanced PLC~, activity in all cell lines expressing autophosphorylated EGFR, further demonstrating the promiscuity of SH2 domain interactions with EGFR phospho-tyrosine motifs. EGF-induced cell movement was noted only in cells which also were responsive by PLC activity. This correlation between the biochemical and biologic responses suggested that PLC~ was the immediate downstream effector.
Specific inhibition of PLC3, was required to demonstrate a causal relationship between this enzyme and cell motility. A specific inhibitor of phospholipase C activity, U73122, was employed to determine whether inhibition of PLC3, would also block induced cell movement. Concurrent exposure of the cells to EGF and U73122 diminished both PLC activity and cell movement. The drug had little effect on the basal rates of either parameter. This agent inhibits all PLC isoforms, and may have some activity towards other phospholipases (32) . To diminish the activation of PLC-/ by EGFR, a dominant-negative PLC fragment, consisting of the Z region (23) , was expressing in select infectant lines. EGFinduction of both PLC activity and cell motility was decreased in these cells. As this fragment is postulated to exert its inhibitory effect by binding to receptor phospho-tyrosine motifs, it is possible that other, non-PLC3, SH2-mediated interactions also are interrupted. The U73122 data points to a phospholipase and the PLCz data indicate a SH2 domain containing molecule as being required for induced cell motility; PLC3, is the only candidate which fulfills both parameters. However, to definitively identify PLC3, as a required intermediary, we down-regulated this enzyme activity by anti-sense oligonucleotides. Cells expressing the WT EGFR were exposed to anti-sense oligonucleotides directed towards two distinct regions of PLC3,. This treatment partially abrogated both PLC activity and motility responses in parallel (Fig. 6) . Thus, PLC~, is required for EGFRmediated movement. These experiments place PLC'y directly downstream of the EGFR.
These findings do not imply that other pathways are not necessary for the full motility response. Kundra and colleagues (25) present evidence that both PLC'y and PI-3' kinase are required for PDGF-BB-induced chemotaxis through a collagen matrix. However, chemotaxis in such an assay results from a number of cell phenotypes, of which cell movement is just one. Therefore, it is not certain that cell movement in itself requires other immediate effector molecules to be activated by the receptor. In addition, certain other signaling pathways may modulate the motility response. Activation of GAP (25) or protein kinase C (PKC) (unpublished observations) limit cell migration; presumably through modulation of net cell adhesiveness. To determine which other signaling pathways, if any, are required to induce cell movement will need similar analyses demonstrating both positive and negative correlations.
EGFR-mediated cell motility is separable from mitogenesis (4, 11), but the level at which the signaling pathways diverge is undefined. PLCq~ activation is not required for EGFinduced mitogenesis as EGFR constructs which do not activate PLC~, can elicit the mitogenic response (16, 48, 52) . We now show that inhibition of PLC3' activity by U73122 or PLCz does not lead to a reduction in the mitogenic response. In fact, in the PLC~-responsive lines, we note a slight but consistent increase in thymidine incorporation in the presence of U73122 (Fig. 7) and in the cells expressing PLCz (Fig. 8) . This may be due to abrogation of feedback inhibition of EGFR signaling by PKC (53); a negative regulatory loop in which PLC3, or PLD (unpublished observations) generates diacylglycerol which then activates PKC. EGFR constructs which are resistant to PKC inhibition (53) are being expressed on NR6 cells to test this postulate. Though these findings do not eliminate the possibility of redundant parallel pathways in signaling mitogenesis as seen with the PDGF receptor (47), they strongly support a divergence of the mitogenic and motogenic signaling pathways by differential activation by the EGFR itself.
We are attempting to define further downstream effector molecules in the motogenic pathway. Signaling through EGFR and related tyrosine kinases activates the MAP ki-nase. This molecule occupies a central station in transducing signals from the extracellular milieu to the nucleus. In addition, MAP kinase elicits numerous cellular responses without involving transcription (28, 31) . We sought to determine if activation of MAP kinase was sufficient to elicit cell motility. In the infectant NR6 cell line which expresses the nonmotogenic c'1000F 992 and c'973 EGFR, EGF exposure increased MAP kinase activity (assessed by MBP phosphorylation) equivalently to the increase seen in WT EGFRexpressing cells (Fig. 9 ). This finding is in agreement with published results using another non-autophosphorylated EGFR in 3T3 cells (16) . We can not determine if MAP kinase is necessary for EGFR-mediated cell motility, either in a parallel pathway or as being permissive for cell movement, due to the lack of nontoxic inhibitors and suitably signalingrestricted EGFR constructs. However, activation of MAP kinase is not sufficient, in itself, to elicit the motogenic response. It is likely that MAP kinase is not involved directly in the EGFR-mediated motogenic signaling pathway, but rather in the mitogenic or other signaling pathways.
